HealthCare Global Enterprises Ltd. Approves Investments in Subsidiaries
March 30, 2026 – HealthCare Global Enterprises Ltd. (NSE: HCG, BSE: 539787) announced that its Board of Directors approved investments in two subsidiaries during a meeting held on March 30, 2026.The company approved an investment of up to INR 98 Crore in HCG NCHRI LLP, a wholly owned subsidiary, and an investment of up to INR 155.66 Crore in Vizag Hospital and Cancer Research Centre Pvt Ltd, a subsidiary of HealthCare Global Enterprises Limited. The investment in Vizag Hospital includes adjustments or incremental payments, as per the terms of a Share Purchase Agreement dated June 28, 2024, with Vizag Hospital and its selling shareholders, with amendment agreements executed on October 01, 2024 and March 29, 2026. This acquisition will increase the company's stake in Vizag Hospital by 34%.
HCG NCHRI LLP Details
HCG NCHRI LLP operates a 74-bedded cancer care centre in Nagpur. For the financial year ended March 31, 2025, its revenue from operations was INR 89.80 Crore and its profit after tax was INR 17.02 Crore. The investment aims to facilitate prepayment and repayment of outstanding borrowings. The transaction aligns with the stated objects of the rights issue approved by the company on February 24, 2026. The investment is expected to be completed in Q1 FY 2027 and will be in the form of cash. The company will continue to hold 100% of the capital in the wholly owned subsidiary.
Vizag Hospital Details
Vizag Hospital, incorporated on March 05, 1986, is engaged in establishing and managing cancer hospitals and diagnostics services. For the financial year ended March 31, 2025, Vizag Hospital’s revenue from operations was INR 110.14 Crore and its profit after tax was INR 18.79 Crore. The acquisition is considered a related party transaction and is being executed at arm’s length. The acquisition of the additional 34% stake will bring the company’s total ownership in Vizag Hospital to 85%. The consideration is in the form of cash, and the investment is expected to be completed in Q1 FY 2027.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.